The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-
modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding …

In a rapidly evolving treatment landscape for multiple sclerosis (MS), the utilization of real-
world observational studies has become increasingly valuable for decisionmaking at the …

Utilizing technology to precisely quantify Parkinson's disease motor symptoms has evolved
over the past 50 years from single point in time assessments using traditional biomechanical …

Background STRIVE was a prospective, 4-year, multicenter, observational, open-label,
single-arm study of natalizumab treatment in anti-JC virus antibody-negative patients with …

Abstract Background Natalizumab (TYSABRI®) 300 mg administered intravenously every-4-
weeks (Q4W) is approved for treatment of relapsing-remitting multiple sclerosis but is …

Aim: Patients with relapsing–remitting multiple sclerosis (RRMS) treated with natalizumab
have anecdotally reported a 'feel-good experience'(FGE). The authors characterized the …

Background In the last years, research on pharmacotherapy and non-pharmacological
approaches to Multiple Sclerosis (MS) has significantly increased, along with a greater …

Aim: To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL)
domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients …

Background: The consideration of patient preference for a certain drug route of
administration (RoA) plays an important role in promoting patient adherence in chronic …

Background In patients with multiple sclerosis (MS), relapses and disability progression
have been associated with decreased health-related quality of life (HRQoL). Methods …